Posted by Michael Wonder on 15 Mar 2022
BeiGene and Medison announce approval and national reimbursement in Israel for Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinaemia
15 March 2022 - Second regulatory approval for Brukinsa in Israel.
BeiGene and Medison Pharma today announced that the State of Israel Ministry of Health has approved Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinaemia.
